|
News
2010
June 10, 2010 – Collegium Pharmaceutical Inc. Receives FDA Fast Track Designation for Tamper Resistant, Chronic Pain Product, COL-172
May 20, 2010 – Collegium Pharmaceutical Inc. Announces Notice of Allowance for Second DETERx™ Technology Patent
March 31, 2010 – Collegium Pharmaceutical Receives Notice of Allowance for US Patent Covering Novel Once-a-Day Formulation of Milnacipran
March 26, 2010 – Collegium Pharmaceutical Inc. Announces Filing of IND for Second Chronic Pain Product Using DETERx™ Tamper-Resistant, Extended Release Technology
February 3, 2010 – Collegium Pharmaceutical Inc. Presents Scientific Poster for
DETERx™ Tamper-Resistant, Extended Release Technology at
American Academy of Pain Medicine’s 26th Annual Meeting
2009
June 30, 2009 – Collegium Pharmaceutical Announces the Sale of AllerNaze™ to
Lupin
June 10, 2009 – Collegium Pharmaceutical Inc. Announces Submission of a Request for Special Protocol Assessment to FDA for Pivotal Trial for Tamper Resistant, Extended Release Opioid (COL-003)
May 26, 2009 – Collegium Pharmaceutical Inc. Announces Notice of Allowance for U.S. Patent Covering its Novel Combination Allergic Rhinitis Product
January 8, 2009 – Collegium Pharmaceutical Announces FDA Approval of AllerNaze™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
2008
July 16, 2008 – Collegium Pharmaceutical Inc. Announces U.S. Patent Issued Covering its DETERx™ Abuse Deterrent Sustained Release Technology
July 15, 2008 – Collegium Pharmaceutical Announces Completion of Series D Financing
May 8, 2008 – Collegium Pharmaceutical Inc. Presents Clinical Data for DETERx™ Abuse-Deterrent Sustained Release Technology at American Pain Society Meeting
April 10, 2008 – Collegium Pharmaceutical’s Partner, BTG, Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnea Patients
April 8, 2008 – Collegium Pharmaceutical Announces FDA Filing for AllerNase™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
February 14, 2008 – Collegium Pharmaceutical Inc. Announces Notice of Allowance for U.S. Patent for its DETERx™ Abuse Deterrent Sustained Release Technology
2007
December 20, 2007 – Collegium Pharmaceutical Inc. Announces Final Study Results of its Successfully Completed Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
December 17, 2007 – Collegium Pharmaceutical to Advance its Allergic Rhinitis Product into Phase III Trials
December 6, 2007 – Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts
October 31, 2007 – Collegium Pharmaceutical Inc. Announces Successful Completion of Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
August 15, 2007 – Collegium Pharmaceutical Provides Update on Development of its Nasal Inhaled Steroid for Allergic Rhinitis
- Expects to file for FDA Approval by the end of 2007
July 12, 2007 – Collegium Pharmaceutical Inc. Announces FDA Acceptance of IND for its Abuse Deterrent Sustained Release Opioid Product
June 15, 2007 – Collegium Pharmaceutical Inc., Announces the Filing of IND for Abuse Deterrent Sustained Release Opioid Product
March 5, 2007 – Collegium Pharmaceutical Announces Successful Completion of Proof of Concept Clinical Trial for Novel Combination Allergic Rhinitis Product
|
